1. Home
  2. MESO vs HMN Comparison

MESO vs HMN Comparison

Compare MESO & HMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • HMN
  • Stock Information
  • Founded
  • MESO 2004
  • HMN 1945
  • Country
  • MESO Australia
  • HMN United States
  • Employees
  • MESO N/A
  • HMN N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • HMN Property-Casualty Insurers
  • Sector
  • MESO Health Care
  • HMN Finance
  • Exchange
  • MESO Nasdaq
  • HMN Nasdaq
  • Market Cap
  • MESO 1.4B
  • HMN 1.7B
  • IPO Year
  • MESO N/A
  • HMN 1991
  • Fundamental
  • Price
  • MESO $10.64
  • HMN $43.39
  • Analyst Decision
  • MESO Buy
  • HMN Buy
  • Analyst Count
  • MESO 4
  • HMN 4
  • Target Price
  • MESO $18.00
  • HMN $46.00
  • AVG Volume (30 Days)
  • MESO 226.6K
  • HMN 339.0K
  • Earning Date
  • MESO 02-26-2025
  • HMN 05-06-2025
  • Dividend Yield
  • MESO N/A
  • HMN 3.22%
  • EPS Growth
  • MESO N/A
  • HMN 75.77
  • EPS
  • MESO N/A
  • HMN 2.76
  • Revenue
  • MESO $5,670,000.00
  • HMN $1,625,600,000.00
  • Revenue This Year
  • MESO $178.09
  • HMN $7.82
  • Revenue Next Year
  • MESO $305.06
  • HMN $5.87
  • P/E Ratio
  • MESO N/A
  • HMN $15.73
  • Revenue Growth
  • MESO N/A
  • HMN 6.67
  • 52 Week Low
  • MESO $5.78
  • HMN $31.81
  • 52 Week High
  • MESO $22.00
  • HMN $44.44
  • Technical
  • Relative Strength Index (RSI)
  • MESO 40.85
  • HMN 58.06
  • Support Level
  • MESO $10.60
  • HMN $42.20
  • Resistance Level
  • MESO $11.26
  • HMN $43.96
  • Average True Range (ATR)
  • MESO 0.41
  • HMN 0.89
  • MACD
  • MESO -0.06
  • HMN 0.03
  • Stochastic Oscillator
  • MESO 12.00
  • HMN 69.03

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The company uses several former teachers in its salesforce. Its segments include Property and Casualty, Supplemental & Group Benefits, Life & Retirement, and Corporate and Other.

Share on Social Networks: